These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 2250943)

  • 21. Management of proliferative diabetic retinopathy.
    Gündüz K; Bakri SJ
    Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth factors and diabetic retinopathy.
    Paques M; Massin P; Gaudric A
    Diabetes Metab; 1997 Apr; 23(2):125-30. PubMed ID: 9137900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes.
    Kinnunen K; Puustjärvi T; Teräsvirta M; Nurmenniemi P; Heikura T; Laidinen S; Paavonen T; Uusitalo H; Ylä-Herttuala S
    Br J Ophthalmol; 2009 Aug; 93(8):1109-15. PubMed ID: 19304585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins.
    Feldmann B; Jehle PM; Mohan S; Lang GE; Lang GK; Brueckel J; Boehm BO
    Growth Horm IGF Res; 2000 Feb; 10(1):53-9. PubMed ID: 10753593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
    Itakura H; Kishi S; Kotajima N; Murakami M
    Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in vitreous concentrations of human hepatocyte growth factor (hHGF) in proliferative diabetic retinopathy: implications for intraocular hHGF production.
    Nishimura M; Ikeda T; Ushiyama M; Kinoshita S; Yoshimura M
    Clin Sci (Lond); 2000 Jan; 98(1):9-14. PubMed ID: 10600653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of vitreous proteins in proliferative diabetic retinopathy.
    Kim SJ; Kim S; Park J; Lee HK; Park KS; Yu HG; Kim Y
    Curr Eye Res; 2006 Mar; 31(3):231-40. PubMed ID: 16531280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy.
    Grant MB; Ellis EA; Caballero S; Mames RN
    Exp Eye Res; 1996 Sep; 63(3):233-44. PubMed ID: 8943696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Glutamate concentration in diabetic vitreous].
    Asensio Sánchez VM; Corral Azor A; Aguirre Aragón B; De Paz García M
    Arch Soc Esp Oftalmol; 2003 Sep; 78(9):493-7. PubMed ID: 14517736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study.
    Fosmark DS; Bragadóttir R; Stene-Johansen I; Berg JP; Berg TJ; Lund T; Sandvik L; Hanssen KF
    Acta Ophthalmol Scand; 2007 Sep; 85(6):618-22. PubMed ID: 17488318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization.
    Grant M; Russell B; Fitzgerald C; Merimee TJ
    Diabetes; 1986 Apr; 35(4):416-20. PubMed ID: 2420665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal neovascular tissue of proliferative diabetic retinopathy: an immunohistochemical study.
    Hosoda Y; Okada M; Matsumura M; Ogino N; Honda Y; Nagai Y
    Ophthalmic Res; 1992; 24(5):260-4. PubMed ID: 1282231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspects of growth hormone control in diabetes.
    Hyer SL; Kohner EM
    Aust N Z J Ophthalmol; 1990 Feb; 18(1):33-9. PubMed ID: 2113400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferative retinopathy with growth hormone deficiency and diabetes mellitus.
    Quin JD; MacCuish AC; Gordon D
    BMJ; 1990 Jun; 300(6739):1586-7. PubMed ID: 2372634
    [No Abstract]   [Full Text] [Related]  

  • 35. Insulin-like growth factor type 1--friend or foe?
    Knott RM
    Br J Ophthalmol; 1998 Jul; 82(7):719-20. PubMed ID: 9924357
    [No Abstract]   [Full Text] [Related]  

  • 36. [Role of growth hormone in proliferative diabetic retinopathy. Clinical and immunohistochemical aspects].
    Negre F; Fredj-Reygrobellet D; Harroche S; Taieb JC
    Ophtalmologie; 1990; 4(1):56-9. PubMed ID: 2250943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free insulin-like growth factor 1 in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case-control study.
    Simó R; Hernández C; Segura RM; García-Arumí J; Sararols L; Burgos R; Cantón A; Mesa J
    Clin Sci (Lond); 2003 Mar; 104(3):223-30. PubMed ID: 12605576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.
    Meyer-Schwickerath R; Pfeiffer A; Blum WF; Freyberger H; Klein M; Lösche C; Röllmann R; Schatz H
    J Clin Invest; 1993 Dec; 92(6):2620-5. PubMed ID: 7504689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy.
    Kakehashi A; Inoda S; Mameuda C; Kuroki M; Jono T; Nagai R; Horiuchi S; Kawakami M; Kanazawa Y
    Diabetes Res Clin Pract; 2008 Mar; 79(3):438-45. PubMed ID: 18053608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of insulin-like growth factor I in the development of diabetic retinopathy].
    Gacka M; Adamiec J
    Przegl Lek; 2003; 60(9):588-92. PubMed ID: 15065339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.